Introduction The development of inhibitors with factor VIII (FVIII) replacement therapy is one
of the most common and challenging complications of haemophilia A (HA) treatment …

Establishing a national screening program for hemophilia patients is highly encouraged by
the World Health Organization and the World Federation of Hemophilia. Hence, this study …

Rare diseases are diseases that occur at low prevalence, and most of them are chronic and
serious diseases that are often life-threatening. Currently, there is no unified definition for …

Abstract Background Hemophilia A and B are caused by variants in the factor (F) VIII or FIX
gene. Selective reporting may influence the distribution of variants reported in genetic …

This chapter first explains the incidence or prevalence of congenital anomalies or genetic
disorders. Many factors influence efforts to accurately determine the incidence or prevalence …

Abstract Background Hemophilia A (HA) is an X-linked congenital bleeding disorder, which
leads to deficiency of clotting factor (F) VIII. It mostly affects males, and females are …

Background: Variants within factor VIII (F8) are associated with sex-linked hemophilia A and
thrombosis, with gene therapy approaches being available for pathogenic variants. Many …

Hemophilia A (HA) is an X-linked recessive bleeding disorder caused by mutations in the F8
gene, resulting in deficient or dysfunctional factor VIII (FVIII). This study aimed to …

Introduction Type of F8 gene mutation is the most important risk factor for inhibitor
development in people with severe hemophilia A. However, there are few large cohort …

Hemophilia A is an X-linked disorder characterized by quantitative deficiency of coagulation
factor VIII (FVIII) caused by pathogenic variants in the factor 8 (F8) gene. Our study's primary …